Tetanus Vaccine

In this experiment, we selected thirteen (13) donors at random and collected blood and immune cells to serve as a pre-vaccination sample. Donors were then immunized with tetanus toxoid vaccine. Presumably, all the donors had previously had this vaccine. Several weeks following vaccine administration, donors were again bled for both serum and immune cells. The immune cells from both pre- and post-vaccination were used to create MIMIC® models, which were stimulated with the vaccine. Thus, each donor served as his or her own control.

We measured serum levels of anti-TT antibodies using ELISA. See graph on left. We measured MIMIC® levels of anti-TT antibodies using the ELISpot assay. See graph on right. This assay detects the presence antigen-specific B cells by reporting a spot on a plate. The results were normalized by counting the number of spots in each culture condition that received the vaccine against the number of spots in parallel cocultures that were left unstimulated (i.e., received no vaccine). The true frequency of B cells in each condition was determined by flow cytometry.

A strong correlation is observed between the serology and ELISpot results, confirming that the MIMIC® System response reproduces the human immune response.

Bar chart: Serum levels of anti-TT antibodies using ELISA compared to MIMIC® levels of anti-TT antibodies using the ELISpot assay